UB Paderborn / Katalog / Suche / in CDI

1 – 15 von 15

Sortiert nach

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

The New England journal of medicine, 2011-02, Vol.364 (6), p.501-513

2011

Volltextzugriff (PDF)

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

Clinical drug investigation, 2023-09, Vol.43 (9), p.699-706

2023

Volltextzugriff (PDF)

Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans

Drug metabolism and disposition, 2012-03, Vol.40 (3), p.539

2012

Volltextzugriff (PDF)

Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells

Toxicological sciences, 2008-11, Vol.106 (1), p.153-161

2008

Volltextzugriff (PDF)

Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

Clinical drug investigation, 2023-09, Vol.43 (9), p.707-708

2023

Volltextzugriff (PDF)

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib

Clinical cancer research, 2009-11, Vol.15 (22), p.7045-7052

2009

Volltextzugriff (PDF)

Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors

Toxicologic pathology, 2008-12, Vol.36 (7), p.905-916

2008

Volltextzugriff (PDF)

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

Cancer chemotherapy and pharmacology, 2009-09, Vol.64 (4), p.691-706

2009

Volltextzugriff (PDF)

The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies

Molecular cancer therapeutics, 2011-11, Vol.10 (11), p.2015-2015

2011

Volltextzugriff (PDF)

Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases

Journal of thoracic oncology, 2011-07, Vol.6 (7), p.1260-1266

2011

Volltextzugriff (PDF)

Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.309-309

2016

Volltextzugriff (PDF)

Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits

Birth defects research. Part B. Developmental and reproductive toxicology, 2009-06, Vol.86 (3), p.204-213

2009

Volltextzugriff (PDF)

Reproductive Toxicity Assessment of Sunitinib, A Multitargeted Receptor Tyrosine Kinase Inhibitor, in Male and Female Rats

Birth defects research. Part B. Developmental and reproductive toxicology, 2012-08, Vol.95 (4), p.267-275

2012

Volltextzugriff (PDF)

Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4118-4118

2012

Volltextzugriff (PDF)

A Multitargeted Receptor Tyrosine Kinase Inhibitor, SU6668, Does Not Affect the Healing of Cutaneous Full-Thickness Incisional Wounds in SKH-1 Mice

Journal of investigative surgery, 2006-07, Vol.19 (4), p.245-254

2006

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(15)

Sprache

Englisch
(15)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Animals
(8)
Female
(8)
Male
(7)
Rats
(6)
Rats, Sprague-Dawley
(6)
Receptor Protein-Tyrosine Kinases - Antagonists & Inhibitors
(6)
Humans
(5)
Indoles - Pharmacokinetics
(5)
Oncology
(5)
Pyrroles - Pharmacokinetics
(5)
Sunitinib
(5)
Indoles - Administration & Dosage
(4)
Indoles - Therapeutic Use
(4)
Pharmacology & Pharmacy
(4)
Pyrroles - Administration & Dosage
(4)
Toxicology
(4)
Adult
(3)
Antineoplastic Agents - Pharmacokinetics
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans

Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells

Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib

Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies

Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases

Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover

Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits

Reproductive Toxicity Assessment of Sunitinib, A Multitargeted Receptor Tyrosine Kinase Inhibitor, in Male and Female Rats

Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET)

A Multitargeted Receptor Tyrosine Kinase Inhibitor, SU6668, Does Not Affect the Healing of Cutaneous Full-Thickness Incisional Wounds in SKH-1 Mice

Suchergebnisse filtern